期刊文献+

脂蛋白脂酶活化剂NO-1886抑制糖尿病兔动脉粥样硬化的形成 被引量:5

Lipoprotein lipase activator NO-1886 suppresses atherosclerosis in aorta of diabetic rabbits
下载PDF
导出
摘要 目的 合成化合物NO 1886 ,一种脂蛋白脂酶活化观察脂蛋白脂酶活化剂是否降低高脂 /高蔗糖饲料诱发的糖尿病新西兰兔的血浆葡萄糖并减轻其动脉粥样硬化。方法 给予高脂 /高蔗糖饲料升高新西兰兔血浆总胆固醇 ,甘油三酯和葡萄糖及降低高密度脂蛋白胆固醇而导致动脉粥样硬化。饲料中加入 1 0 %NO 1886进行治疗观察。分别在 0、4、8、12、16、2 0及 2 4wk从禁食过夜的兔耳静脉抽取血样测定葡萄糖和脂质水平。第 2 4周末 ,处死动物 ,分离主动脉 ,经苏丹Ⅳ染色固定脂质后 ,计算脂纹病变面积。结果 应用NO 1886后 ,实验动物血浆葡萄糖 ,总胆固醇和甘油三酯降低 ,高密度脂蛋白胆固醇增加。对动脉粥样硬化的发展具有抑制作用。结论 NO 1886不仅可改善脂质紊乱 ,而且可降低血浆葡萄糖 。 AIM To ascertain whether NO 1886 lowers plasma glucose and suppresses atherosclerosis in high fat/high sucrose induced diabetic New Zealand white rabbits. METHODS 1 0% NO 1886 was supplemented into the high fat/high sucrose feed for treating the rabbits for 20 weeks. Blood samples for glucose and lipid measurements were withdrawn from auricular veins at weeks 0, 4, 8, 12, 16, 20 and 24 after fasting overnight. The fatty streak lesions of the aortas were quantified following lipid staining with Sudan Ⅳ. RESULTS NO 1886 resulted in decreased plasma glucose, total cholesterol and triglyceride levels and increased HDL C levels. Furthermore, NO 1886 provided protection against the development of atherosclerosis in the aorta. CONCLUSION NO 1886 not only ameliorates the lipid disorder, but also lowers plasma glucose level, and suppresses atherosclerosis in the aorta of diabetic rabbits.
出处 《中国药理学通报》 CAS CSCD 北大核心 2001年第4期417-420,共4页 Chinese Pharmacological Bulletin
基金 教育部留学回国人员科研启动基金 日本大冢制药厂新药研究基金 湖南省卫生厅课题( 985 0 )资助
关键词 NO-1886 动脉粥样硬化 糖尿病 脂蛋白脂酶活化剂 NO-1886 glucose atherosclerosis diabetes rabbits
  • 引文网络
  • 相关文献

参考文献1

  • 1Zavaroni I,Metabolism,1982年,31卷,11期,1077页

同被引文献49

  • 1Smith SA. Peroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolism. Biochem Soc Trans, 2002, 30 (Pt 6): 1 086-090
  • 2Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol, 2002, 13 (2): 155-164
  • 3Kern PA. Potential role of TNFalpha and lipoprotein lipase as candidate genes for obesity. J Nutr, 1997, 127 (9): 1 917S- 922S
  • 4Ruan H, Pownall HJ, Lodish HF. Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. J Biol Chem, 2003, 278 (30): 28 181-192
  • 5Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, Nakagawa S, et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology, 2003, 124 (5): 1 315-324
  • 6Yin W, Liao D, Wang Z, Xi S, Tsutsumi K, Koike T, et al. NO-1886 inhibits size of adipocytes, suppresses plasma levels of tumor necrosis factor-alpha and free fatty acids, improves glucose metabolism in high-fat/high-sucrose-fed miniature pigs. Pharmacol Res, 2004, 49 (3): 199-206
  • 7Schreyer SA, Wilson DL, LeBoeuf RC. C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis. Atherosclerosis, 1998, 136: 17-24
  • 8Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA, 1997, 94 (9): 4 312-317
  • 9Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology, 2003, 144 (6): 2 201-207
  • 10Ram VJ. Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation. Prog Drug Res, 2003, 60: 93-132

引证文献5

二级引证文献12

;
使用帮助 返回顶部